(MedPage Today) — An investigational endoscopic procedure showed a trend for reducing weight rebounds after patients with obesity discontinued the GLP-1 agonist tirzepatide (Zepbound), according to preliminary results from the REMAIN-1 trial…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
